E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

gear headHow cool is this? Shampoo for men in a quart of oil bottle!

Click the banner to get some now and tell the little lady to throw that other stuff in the trash!
DEPOMED  
DEPOMED
DEPOLast: $3.31 ($+0.05)Volume: 568,513Last Trade: 8/5/2010 5:20:01 PM
Today

Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year
 Options
Quote |  Alerts | | Free Newsletter
 
 Detailed Quote
NASDAQ:DEPO $3.31 ($+0.05 +1.5337%)
Industry: Health Sector: Pharmaceuticals
Open: 3.26 Previous Close: 3.26
Day's High: 3.34 Day's Low: 3.24
52-Week High: 5.24 52-Week Low: 1.69
 
Bid: 3.31 / 17,700 Ask: 3.32 / 9,200
Volume: 568,513 Outstanding: 47,764,745
Market Cap: $158 M
DEPOMED Profile
DepoMed is a specialty pharmaceutical company engaged in the development and commercialization of products that are based on its proprietary oral drug delivery technologies. As of Dec 31 2006, Co. has developed two commercial products: Glumetza? , a once-daily treatment for adults with type 2 diabetes that Co. jointly commercializes in the U.S. with King Pharmaceuticals, Inc., and ProQuin XR , a once-daily treatment for uncomplicated urinary tract infections that Esprit Pharma, Inc. markets in the U.S. In addition, Co. has a product candidate, Gabapentin GR? , currently in a Phase 3 trial for the treatment of postherpetic neuralgia.
 DEPOMED News & Press Releases

Depomed to Announce Second Quarter 2010 Financial Results on August 5, 2010
MENLO PARK, Calif., July 29, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. ( DEPO ) announced today that it will release second quarter 2010 financial results a... [more]

Depomed Announces Receipt of a $10 Million Milestone Payment for DM-1796
MENLO PARK, Calif., June 28, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. ( DEPO ) today announced that it has received a $10 million milestone payment from Ab... [more]

Depomed to Present at the BioCentury and Thomson Reuters Future Leaders In The Biotech Industry Conf
Depomed, Inc. ( DEPO ) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the BioCentury and Thomson Reuters... [more]

Depomed Announces Submission of New Drug Application for Investigational Postherpetic Neuralgia Trea
Depomed, Inc. ( DEPO ) today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA)... [more]

Depomed Reports Fourth Quarter and Year-End 2009 Financial Results
Depomed, Inc. ( DEPO ) today reported financial results for the fourth quarter and year ended December 31, 2009. “The fourth quarter of 2009 saw the... [more]

Depomed Completes Enrollment of Breeze 1 Phase 3 Clinical Trial for Non-Hormonal Treatment in Menopa
Depomed, Inc. ( DEPO ) announced today that it has completed enrollment of Breeze 1, the first of two pivotal Phase 3 clinical trials in Depomed's registration... [more]

Depomed’s License Agreement With Solvay Pharmaceuticals Clears HSR Review
Depomed, Inc. ( DEPO ) announced today that the previously announced product license agreement under which Solvay Pharmaceuticals will have exclusive rights fo... [more]

Depomed, Inc. Announces Conference Call to Discuss Exclusive North American License Agreement with S
Depomed, Inc. ( DEPO ), a specialty pharmaceutical company with a proven, proprietary technology, AcuForm, announced today that it will be hosting a conference... [more]

Depomed to Present at the 7th Annual Needham & Co. Biotechnology & Medical Technology Conference
Depomed, Inc. ( DEPO ) today announced that president and chief executive officer, Carl A. Pelzel, will present on Thursday, June 12, 2008 at 10:00 a.m. ET dur... [more]

QED International Associates Announces Quarterly Rebalancing of ...
PR Newswire (press release): QED International Associates Announces Quarterly Rebalancing of ... , NY - Mar 19, 2008 Ltd. Tokyo: 4523 Mylan, Inc. NYSE: MYL Metabolic-Endocrine Disorders Index (HHM) Drop Depomed Inc. NASDAQ: DEPO Emisphere Technologies Inc. NASDA

Depomed Reports Preliminary 2007 Year End Financial Results
PharmaLive.com (press release): Mar 6, 2008 - Depomed, Inc. ( NASDAQ:DEPO ) today reported preliminary financial results for the year ended December 31, 2007. ...

Terminated deals boost Depomed profit
San Antonio Business Journal: , TX - Mar 7, 2008 The Menlo Park company ( NASDAQ: DEPO ) lost $39.7 million in 2006. A one-time gain of $29.6 million from a terminated promotion deal with King ...

Depomed to Present at the Rodman & Renshaw Acumen BioFin 4th ...
Therapeutics Daily (subscription) (press release): Apr 30, 2007 - Depomed, Inc. ( NASDAQ:DEPO ) today announced that chairman, president and chief executive officer, John W. Fara, Ph.D., ...

4th Annual Rodman & Renshaw Acumen BioFin Global Healthcare
Business Wire (press release): Depomed, Inc. ( NASDAQ:DEPO ) today announced that chairman, president and chief executive officer, John W. Fara, Ph.D., will present on ...

Depomed to Announce First Quarter 2007 Financial Results on ...
PharmaLive.com (press release): Apr 25, 2007 - Depomed, Inc. ( NASDAQ:DEPO ) today announced that it will release first quarter results for 2007 after the market closes on ...

Depomed Completes $20 Million Registered Direct Offering
PharmaLive.com (press release): Apr 23, 2007 - Depomed, Inc. ( NASDAQ:DEPO ) announced today that it has completed a self-managed registered direct offering for $20 million ...

Depomed to Present at the CIBC World Markets Annual Biotechnology ...
Therapeutics Daily (subscription) (press release): Apr 4, 2007 - Depomed, Inc. ( NASDAQ:DEPO ) today announced that chairman, president and chief executive officer, John W. Fara, Ph.D., ...


Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright © 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts